Enfuvirtide Side Effects: Safety Signals and Warnings
Enfuvirtide safety concerns are compound-specific. The main listed side effects are Injection site reactions (nearly universal), Diarrhea, and Nausea. The main warning signals are Injection site reactions are nearly universal - rotate sites and monitor for infection, Hypersensitivity reactions including immune-mediated reactions reported, and Increased rate of bacterial pneumonia observed in clinical trials.
Direct Answer
Enfuvirtide (Fuzeon) is FDA-approved for HIV-1 treatment in adults with ongoing viral replication despite prior antiretroviral therapy. It is the first fusion inhibitor approved and works at a mechanistically distinct step from all other ARV classes. Phase 3 data from TORO-1 and TORO-2 trials showed significant viral suppression in treatment-experienced patients. Its twice-daily subcutaneous injection requirement limits real-world use, but the evidence is solid.
- Evidence grade
- Level A
- Research status
- FDA Approved
- Category
- Immune Support
- Best for
- HIV-1 treatment in antiretroviral-experienced patients, HIV fusion inhibitor pharmacology
Reported Side Effects
- Injection site reactions (nearly universal)
- Diarrhea
- Nausea
- Fatigue
- Insomnia
- Peripheral neuropathy
- Increased pneumonia risk
Warnings
- Injection site reactions are nearly universal - rotate sites and monitor for infection
- Hypersensitivity reactions including immune-mediated reactions reported
- Increased rate of bacterial pneumonia observed in clinical trials
- Not recommended as first-line therapy - reserve for treatment-experienced patients
- Monitor for signs and symptoms of Guillain-Barre syndrome
Known or Plausible Interactions
- Other antiretrovirals (used in combination - adjust based on regimen)
- No significant CYP450 interactions due to peptide metabolism
- Tipranavir/ritonavir (modestly increased enfuvirtide levels)
Regulatory Context
FDA-approved (2003) for HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. Available by prescription only. Marketed as Fuzeon by Roche/Trimeris.
Evidence Snapshot
| Evidence grade | Level A |
|---|---|
| Research status | FDA Approved |
| Best supported outcomes | HIV Viral Load Reduction (Level A), CD4 Count Improvement (Level A), and Injection Site Reactions (Level A) |
| Primary citation count | 3 |
| Last reviewed | 2026-06-02 |
Related Guides
How to Cite This Page
ExaminePeptides. "Enfuvirtide Side Effects: Safety Signals and Warnings." Last reviewed 2026-06-02. https://examinepeptides.com/answers/enfuvirtide-side-effects-safety/
This static answer page is built for fast indexing and direct citation. It summarizes the matching full evidence review and links back to primary sources where the source database includes them.